Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

    • Efficacy and Safety of Autologous Adipose Tissue-Derived Stromal Vascular Fraction in Patients with Premature Ovarian Insufficiency: Protocol for a Single-Centre Randomised Controlled Trial

    Yaodong Zhang, Hui Liu, Yanru Lou,Jialin Li, Chenhong Liu, Hongxia Zhang, Chen Zhang, Qing Guo, Xiaojuan Liu,Wan Yang, Jia Li, Tian,Lin Zeng,Huiyu Xu,Shuo Yang,Xiumei Zhen,Hongsen Bi,Rui Yang,Yang Yu,Caihong Ma,Rong Li,Ping Liu,Jie Qiao

    BMJ open（2025）

    Department of Endocrinology and Metabolism | Department of Plastic Surgery | Department of Medicine | 8 ORBIS International | Research Center of Clinical Epidemiology | Department of Obstetrics and Gynecology | 6 Department of Plastic Surgery | Department of Hepatobiliary and Pancreatic Surgery | The Second Hospital & Clinical Medical School | 8 Gynecological Oncology Center | Capital Medical University Electric Power Teaching Hospital | professor

    Cited 0|Views2
    Abstract
    INTRODUCTION:Premature ovarian insufficiency (POI) is a complicated reproductive endocrine disease seriously affecting physiological function and fertility in women. Its clinical features include amenorrhoea or infrequent menstruation, oestrogen deficiency and elevated levels of gonadotropins. At present, conventional treatments for POI in clinical practice are unable to fundamentally improve ovarian function or solve fertility problems, and often have certain side effects. Adipose tissue-derived stromal vascular fraction (SVF) contains various cell types, including adipose-derived stem/stromal cells, stromal cells, endothelial cells, fibroblasts and macrophages. Recently, SVF has shown tremendous potential in treating many refractory diseases, offering a promising therapeutic option for improving ovarian function. Although SVF has shown therapeutic effects in animal models of POI, there is insufficient evidence demonstrating the efficacy and safety of autologous SVF in women with POI. METHODS AND ANALYSIS:This study is a single-centre randomised controlled trial designed to explore the efficacy and safety of using autologous SVF in improving pregnancy outcomes in patients with infertility diagnosed with POI. A total of 308 women meeting the eligibility criteria will be randomly assigned in a 1:1 ratio to either the SVF group or the control group. The control group will receive conventional assisted reproductive technology treatment, including in vitro fertilisation, embryo transfer and intracytoplasmic sperm injection. In the SVF group, patients will undergo bilateral intraovarian injections of the SVF suspension under ultrasound guidance. Their in vitro fertilisation cycles will commence 4-8 weeks after SVF injection. The primary outcome of this trial is the cumulative clinical pregnancy rate within 6 months. Aside from this, secondary outcomes including menstrual volume and duration, ovarian volume, antral follicle count, and serum levels of anti-mullerian hormone and sex hormone (oestrogen and follicle-stimulating hormone) will be measured. All adverse events will be monitored and recorded within a 6-month follow-up period. Additionally, pregnancy outcomes and the health status of the offspring will be tracked through telephone follow-up for 2 years. ETHICS AND DISSEMINATION:This trial has been reviewed and approved by the Ethics Committee of Peking University Third Hospital (approval number: IRB00006761-M2024330). We will ensure that each patient has signed informed consent before participation in the trial. The findings will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER:NCT06481969.
    More
    Translated text
    求助PDF
    上传PDF
    View via Publisher
    Bibtex
    AI Read Science
    AI Summary
    AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
    Example
    Background
    Key content
    Introduction
    Methods
    Results
    Related work
    Fund
    Key content
    • Pretraining has recently greatly promoted the development of natural language processing (NLP)
    • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
    • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
    • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
    • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
    Upload PDF to Generate Summary
    Must-Reading Tree
    Example
    Generate MRT to find the research sequence of this paper
    Data Disclaimer
    The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
    Chat Paper
    【要点】：本研究旨在探究自体脂肪组织来源的血管基质细胞（SVF）治疗女性早发性卵巢功能不全（POI）的有效性和安全性，是一项单中心随机对照试验。
    

    【方法】：研究采用随机对照试验设计，将符合条件的308名女性按照1:1的比例随机分配到SVF组或对照组，对照组接受常规辅助生殖技术治疗，SVF组则接受超声引导下的双侧卵巢内SVF悬液注射。
    

    【实验】：实验将跟踪记录所有参与者在6个月内的不良事件，并通过电话随访2年以跟踪妊娠结果和后代健康状况，数据集名称未在摘要中提及。